Woodline Partners LP lifted its position in shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN - Free Report) by 124.8% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 423,828 shares of the specialty pharmaceutical company's stock after buying an additional 235,257 shares during the quarter. Woodline Partners LP owned approximately 0.77% of Supernus Pharmaceuticals worth $15,326,000 at the end of the most recent quarter.
A number of other hedge funds and other institutional investors have also made changes to their positions in SUPN. Raiffeisen Bank International AG bought a new stake in Supernus Pharmaceuticals during the fourth quarter valued at about $25,000. Smartleaf Asset Management LLC raised its stake in shares of Supernus Pharmaceuticals by 219.1% in the fourth quarter. Smartleaf Asset Management LLC now owns 1,267 shares of the specialty pharmaceutical company's stock worth $47,000 after purchasing an additional 870 shares during the last quarter. Mark Sheptoff Financial Planning LLC purchased a new position in shares of Supernus Pharmaceuticals in the fourth quarter worth about $52,000. Headlands Technologies LLC raised its position in Supernus Pharmaceuticals by 203.0% during the fourth quarter. Headlands Technologies LLC now owns 1,515 shares of the specialty pharmaceutical company's stock valued at $55,000 after acquiring an additional 1,015 shares in the last quarter. Finally, Newbridge Financial Services Group Inc. purchased a new stake in shares of Supernus Pharmaceuticals in the fourth quarter valued at approximately $72,000.
Supernus Pharmaceuticals Trading Up 1.2%
SUPN traded up $0.40 during mid-day trading on Tuesday, hitting $32.50. 36,986 shares of the stock were exchanged, compared to its average volume of 533,602. The firm's fifty day moving average is $31.98 and its two-hundred day moving average is $34.70. Supernus Pharmaceuticals, Inc. has a 1-year low of $25.53 and a 1-year high of $40.28. The company has a market cap of $1.82 billion, a PE ratio of 30.37 and a beta of 0.74.
Analysts Set New Price Targets
A number of research firms have recently commented on SUPN. Wall Street Zen upgraded Supernus Pharmaceuticals from a "buy" rating to a "strong-buy" rating in a research report on Friday, May 16th. Cantor Fitzgerald reiterated a "neutral" rating and set a $36.00 price target on shares of Supernus Pharmaceuticals in a report on Wednesday, February 26th.
Check Out Our Latest Stock Analysis on Supernus Pharmaceuticals
About Supernus Pharmaceuticals
(
Free Report)
Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age.
See Also
Before you consider Supernus Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Supernus Pharmaceuticals wasn't on the list.
While Supernus Pharmaceuticals currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
